These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8486567)

  • 1. Leishmaniasis: some recent developments in chemotherapy.
    Cook GC
    J Antimicrob Chemother; 1993 Mar; 31(3):327-30. PubMed ID: 8486567
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacology of leishmaniasis.
    Balaña-Fouce R; Reguera RM; Cubría JC; Ordóñez D
    Gen Pharmacol; 1998 Apr; 30(4):435-43. PubMed ID: 9580315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical status of agents being developed for leishmaniasis.
    Berman J
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1337-46. PubMed ID: 16255674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: leishmaniasis: an update of current pharmacotherapy.
    Arya SC; Agarwal N
    Expert Opin Pharmacother; 2013 Jun; 14(9):1275-6. PubMed ID: 23621855
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic options for visceral leishmaniasis].
    Desjeux P
    Med Mal Infect; 2005 Jun; 35 Suppl 2():S74-6. PubMed ID: 15978396
    [No Abstract]   [Full Text] [Related]  

  • 6. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 7. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paromomycin in the treatment of leishmaniasis.
    Sundar S; Chakravarty J
    Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
    Ortega V; Giorgio S; de Paula E
    J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heated amphotericin to treat leishmaniasis.
    Bau P; Bolard J; Dupouy-Camet J
    Lancet Infect Dis; 2003 Apr; 3(4):188. PubMed ID: 12679259
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN; Croft SL
    Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effectiveness of paromomycin-I against Leishmania garnhami in heterozygote albino mice].
    Rezzano de Raffo S; Moreno G; García J; Scorza JV
    Rev Cubana Med Trop; 1985; 37(1):55-65. PubMed ID: 3915382
    [No Abstract]   [Full Text] [Related]  

  • 13. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
    Rezzano S; Armas JA; Moreno G; Scorza JV
    Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous leishmaniasis. Treatment with itraconazole.
    Albanese G; Giorgetti P; Santagostino L; Crippa D; Sala G
    Arch Dermatol; 1989 Nov; 125(11):1540-2. PubMed ID: 2554818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrences of visceral leishmaniasis caused by Leishmania siamensis after treatment with amphotericin B in a seronegative child.
    Osatakul S; Mungthin M; Siripattanapipong S; Hitakarun A; Kositnitikul R; Naaglor T; Leelayoova S
    Am J Trop Med Hyg; 2014 Jan; 90(1):40-2. PubMed ID: 24277788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the management of visceral leishmaniasis.
    Sundar S; Kumar A
    Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
    [No Abstract]   [Full Text] [Related]  

  • 19. Eliminating visceral leishmaniasis in South Asia: the road ahead.
    Rijal S; Sundar S; Mondal D; Das P; Alvar J; Boelaert M
    BMJ; 2019 Jan; 364():k5224. PubMed ID: 30670453
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical guide for the treatment of leishmaniasis.
    Davidson RN
    Drugs; 1998 Dec; 56(6):1009-18. PubMed ID: 9878989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.